Search results
Aug 7, 2023 · Saw palmetto can affect blood-clotting and may increase your risk of bleeding. If you need surgery, dental work, or a medical procedure, stop taking saw palmetto at least 2 weeks ahead of time. Call your doctor if the condition you are treating with saw palmetto does not improve, or if it gets worse while using this product.
- (31)
Oct 16, 2023 · You are taking warfarin or other blood thinners: Saw palmetto may increase the risk of bruising and bleeding. You are taking antiplatelets such as clopidogrel: Saw palmetto may increase the effects of these drugs. You are taking nonsteroidal anti-inflammatory drugs (NSAIDs): Saw palmetto may increase the side effects of these drugs.
People also ask
Does saw palmetto cause liver damage?
Can saw palmetto cause hepatitis?
Does saw palmetto cause adverse events?
Apr 2, 2020 · Hepatotoxicity from saw palmetto is very rare and cases have been self-limiting upon stopping the herbal. There have been no instances leading to fatalities, liver transplantation, chronic hepatitis, or vanishing bile duct syndrome. Studies of rechallenge have not been reported. Other Names: Cabbage palm, Sabal.
- 2020/04/02
Apr 12, 2019 · More serious side effects like liver damage, pancreatitis, bleeding in the brain, and death have been reported in isolated cases. However, it isn’t always clear whether saw palmetto was...
Taking saw palmetto along with medications that also slow blood clotting might increase the risk of bruising and bleeding. Birth control pills (Contraceptive drugs) interacts with SAW PALMETTO
Oct 7, 2022 · Saw palmetto can also increase the risk of bleeding by affecting the body’s blooding-clotting ability and interfering with the activity of blood thinners like warfarin and coumadin. Saw palmetto may also impact the absorption of iron by the body.
Results. There were no significant differences observed between the saw palmetto and placebo-allocated participants in the risk of suffering at least one serious adverse event (5.4% vs. 9.7%, respectively; p = 0.31) or non-serious symptomatic adverse event (34.8% vs. 30.1%; p = 0.48).
